IFN-γ enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics

Because cytokines have been utilized in treatment of sepsis in neonates, we studied the effects of interferon-γ (IFN-γ) and GM-CSF on killing of intracellular methicilin-resistant Staphylococcus aureus (MRSA) by human monocyte derived macrophages (MDM) in the presence of daptomycin (Dap), rifampin (...

Full description

Saved in:
Bibliographic Details
Published inCytokine (Philadelphia, Pa.) Vol. 51; no. 3; pp. 274 - 277
Main Authors Smith, Raymond P., Baltch, Aldona L., Ritz, William J., Michelsen, Phyllis B., Bopp, Lawrence H.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.09.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Because cytokines have been utilized in treatment of sepsis in neonates, we studied the effects of interferon-γ (IFN-γ) and GM-CSF on killing of intracellular methicilin-resistant Staphylococcus aureus (MRSA) by human monocyte derived macrophages (MDM) in the presence of daptomycin (Dap), rifampin (Rif), gentamicin (Gen), and combinations of these drugs. MDM infected with MRSA were treated with Dap (1 × MIC), Gen (0.5 × MIC), or Rif (1 × MIC), singly or in combination, with or without cytokines. MDM were lysed and viable bacteria counted. With antibiotics, MDM activated by IFN-γ had a more rapid and prolonged bacterial killing effect than MDM activated by GM-CSF. This effect was most obvious with the triple-drug combination. In contrast, GM-CSF reduced intracellular killing under most experimental conditions compared to the effect of antibiotics alone. Dap alone and two- and three-drug combinations demonstrated significant killing effect for the 48 h of the assay. IFN-γ enhanced rapid intracellular killing of MRSA in the presence of triple-drug treatment or Dap alone. GM-CSF in combination with the antibiotics reduced killing under most conditions studied. Further studies to confirm these observations with IFN-γ-activated MDM and other MRSA strains are needed to support clinical trials for difficult-to-treat MRSA infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1043-4666
1096-0023
DOI:10.1016/j.cyto.2010.06.004